My­lan to pay for EpiPen over­charges

The Myanmar Times - - International Business -

MY­LAN will pay US$465 mil­lion to re­solve ac­cu­sa­tions from some reg­u­la­tors that it over­billed the fed­eral Med­i­caid pro­gram for the EpiPen al­lergy med­i­ca­tion.

The set­tle­ment with the US Depart­ment of Jus­tice and some other reg­u­la­tors re­solves ques­tions about My­lan’s clas­si­fi­ca­tion of EpiPen as a generic drug, the drug­maker said. My­lan said it did not ad­mit fault in the agree­ment.

Fed­eral health reg­u­la­tors have said the mis­clas­si­fi­ca­tion con­trib­uted to a swelling of pay­ments to My­lan, which nearly mo­nop­o­lises the mar­ket for the al­lergy in­jec­tors, for EpiPen un­der fed­eral health care pro­grams.

Had EpiPen been cor­rectly clas­si­fied, My­lan would have been forced to pay higher re­bates to fed­eral and state of­fi­cials, of­fi­cials with the US Cen­ter for Medi­care and Med­i­caid Ser­vices (CMS) have said.

My­lan, which has been un­der strong at­tack from politi­cians and the pub­lic for jack­ing up the price of EpiPens – es­sen­tial for se­vere al­lergy suf­fer­ers to block life-threat­en­ing at­tacks – touted the set­tle­ment.

De­spite news of the set­tle­ment, My­lan al­luded to a fresh fed­eral in­ves­ti­ga­tion in an SEC fil­ing, say­ing it had re­ceived a doc­u­ment re­quest from en­force­ment of­fi­cials “seek­ing com­mu­ni­ca­tions with the CMS and doc­u­ments con­cern­ing My­lan prod­ucts sold and re­lated to the Med­i­caid Drug Re­bate Pro­gram, and any re­lated com­plaint”. -

Newspapers in English

Newspapers from Myanmar

© PressReader. All rights reserved.